2 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Ju Hyun Shim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients Regorafenib (BAY 73-4506) - Carcinoma, Hepatocellular, Hepatic Insufficien | Phase 2 | Not yet recruiting | Ju Hyun Shim | 20 | 2026-03-15 | 2026-04-07 |
| Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial Regorafenib (BAY 73-4506) - Carcinoma, Hepatocellular, Lenvatinib | Phase 2 | Not yet recruiting | Ju Hyun Shim | 24 | 2026-03-15 | 2026-04-07 |
Carcinoma, Hepatocellular (2) · Disease Progression (1)
regorafenib (2)
South Korea (2)